Posted by Adam Awdish on
Suman Dutta, Simon Hornung, Adira Kruayatidee, Katherine N. Maina, Irish del Rosario, Kimberly C. Paul, Darice Y. Wong, Aline Duarte Folle, Daniela Markovic, Jose-Alberto Palma, Geidy E. Serrano, Charles H. Adler, Susan L. Perlman, Wayne W. Poon, Un Jung Kang, Roy N. Alcalay, Miriam Sklerov, Karen H. Gylys, Horacio Kaufmann, Brent L. Fogel, Jeff M. Bronstein, Beate Ritz & Gal Bitan
May 15, 2021
Diagnosing Parkinson’s disease (PD) and other atypical parkinsonian syndromes is difficult because there currently are no known biomarkers that are easily accessible and reliable. Multiple system atrophy (MSA) is a synucleinopathy that exhibits symptoms that often overlap with those of PD. Researchers in this study hypothesized that there may be CNS biomarkers that could be isolated from the plasma or serum to give insights onto the brain’s biochemistry and potentially diagnose these diseases.
The researchers isolated exosomes from the plasma and serum from healthy control patients, patients with PD, and patients with MSA and used an electro-chemiluminescence ELISA to measure their levels. They found that both PD and MSA patients had higher α-syn concentrations than healthy control patients, however MSA patients had significantly higher levels than PD patients.
Related products available from Innovative Research also include: